Telix Pharmaceuticals shares rose ~11% on Tuesday, continuing a two-day gain following US FDA approval of Pixclara, the first FET-PET imaging agent for glioma. CEO Christian Behrenbruch highlighted Pixclara's potential as a platform and noted complementary therapeutic progress with TLX-101 in phase 3 trials for glioblastoma multiforme.